Opinion|Videos|August 13, 2026
FLAME Data and the Role of ctDNA
Author(s)Sandip Patel, MD, Amy Cummings, MD, PhD,
The faculty examine circulating tumor DNA (ctDNA) as a tool for treatment selection.
Advertisement
The faculty examine circulating tumor DNA (ctDNA) as a tool for treatment selection. The panel walks through the FLAME study, which enrolled patients with EGFR mutations, started all patients on osimertinib, reassessed ctDNA at 3 weeks, and randomized those with persistent detectable ctDNA to escalation with chemotherapy or continued monotherapy. Patients who remained on monotherapy despite detectable ctDNA did worse.
Advertisement
Related to this article
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
Revisit Every OncLive On Air Episode From September 2026
2
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
3
Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer
4
UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma
5